Chronic obstructive pulmonary disease can gradually limit a person’s ability to breathe, move and maintain independence. Current treatments can help manage symptoms, but they do not reverse all the damage associated with the disease. SMSbiotech is investigating whether a different kind of cell therapy could support the body’s own repair processes.
The California biotechnology company is developing a proprietary platform called Small Mobile Stem cells, or SMS Cells. Derived from adult human blood, these cells are being studied for their potential to interact with the body’s existing cells involved in tissue repair.
The approach differs from cell therapies designed primarily to replace damaged tissue. SMSbiotech’s hypothesis is that its cells could influence native repair pathways. That remains an investigational premise, and its clinical significance must be established through controlled studies.
A cell platform designed for practical delivery
SMSbiotech’s lead programme focuses on COPD. The company is studying SMS Cells delivered directly to the lungs through nebulized inhalation, using an established type of delivery device.
The rationale is straightforward: if the target organ is the lung, inhalation may offer a direct route for administering the investigational cells. But delivery alone does not establish therapeutic benefit. Researchers must determine whether the cells can be administered safely, reach the intended tissues and produce meaningful effects.
The company describes its SMS Cells as small, mobile and derived from adult blood. It says preclinical research has found interactions between these cells and selected resident cell populations associated with tissue repair. SMSbiotech calls this proposed mechanism Targeted Multi-Gene Activity Modulation, or TMAM.
These descriptions reflect the company’s research model. They should not be interpreted as proof that the cells regenerate damaged lung tissue in patients.
From discovery to clinical testing
Dr. Abdulkader Rahmo founded SMSbiotech in 2015, drawing on his research into the cell population that underpins the platform. He serves as co-founder, president and chief scientific officer. His background includes biochemistry, academic research, clinical laboratory medicine and biomanufacturing.
The transition from a research discovery to a clinical programme requires more than identifying a potentially useful cell. A therapy must be manufactured consistently, tested for quality and evaluated in patients under a defined protocol.
SMSbiotech has established an in-house, clinical-grade manufacturing facility in San Diego. The company says its allogeneic approach allows cells to be produced and quality-tested ahead of treatment, rather than manufactured separately for each patient.
That model could, if validated, make supply more predictable. Yet repeatable production is only one part of the development challenge. The company must also establish reliable release criteria, appropriate storage conditions and a treatment regimen supported by clinical evidence.
What the COPD programme has shown so far
SMSbiotech is conducting a Phase 1b study in Australia, evaluating nebulized SMS Cells in ascending-dose cohorts. The company reported that the first cohort completed its protocol-specified 28-day safety monitoring without therapy-related adverse events, with dose escalation proceeding.
In September 2026, the U.S. Food and Drug Administration issued a “Study May Proceed” notification following review of the company’s Investigational New Drug application. This allows SMSbiotech to initiate a U.S. clinical study under that application. It is not FDA approval of the therapy.
The company has targeted first U.S. patient dosing for the fourth quarter of 2026. It has also discussed further clinical development, including a possible Phase 2a programme, contingent on the results of its ongoing research.
Early observations reported by a company in a small trial are not proof of efficacy. Larger, controlled studies will be needed to determine whether the treatment can improve outcomes for people with COPD.
The platform at a glance
– Cell source: Adult human blood-derived cells.
– Lead indication: Chronic obstructive pulmonary disease.
– Delivery approach: Investigational nebulized administration.
– Clinical status: Phase 1b development in Australia; U.S. study cleared to proceed under an IND.
– Manufacturing: Company-operated facility intended to support clinical-grade production.
Leadership and the work ahead
Rahmo’s scientific leadership is supported by a team covering clinical development, finance and business development. Dr. Jason Kirkness serves as chief clinical officer, while Michael Swartzburg is chief financial officer. Joe Kiani, the founder and former chief executive of Masimo, became SMSbiotech’s chairman in February 2026.
The mix reflects the company’s current stage. Scientific development must progress alongside clinical planning, financing, manufacturing controls and decisions about which indications to pursue.
COPD is the near-term focus, but SMSbiotech is also exploring possible applications in other respiratory, orthopedic, cardiovascular and chronic degenerative conditions. Those areas represent potential research directions, not established treatment uses.
For a cell platform to become a medicine, broad biological possibilities must eventually narrow into specific candidates, doses and patient populations. That process can take years and may not lead to approval.
The measure will be evidence
SMSbiotech is pursuing a regenerative approach in a field where many patients continue to face chronic disease despite existing care. Its blood-derived cell platform and inhaled delivery strategy provide a distinctive basis for investigation.
The next milestones are clinical, not merely technical. Researchers must assess safety in more participants, determine whether the treatment produces a meaningful benefit and establish how consistently it can be manufactured and administered.
If those questions are answered convincingly, SMSbiotech could contribute a new approach to regenerative medicine. Until then, its platform remains an investigational technology whose promise must be judged by the evidence emerging from clinical studies.
